Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05350410
Other study ID # HALT-AD
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 5, 2022
Est. completion date August 24, 2022

Study information

Verified date November 2022
Source Alzheimer's Disease Cooperative Study (ADCS)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This initial four-months pilot study will focus on at least three educational courses (introduction to dementia and lifestyle risk factors, sleep and diet). It may also include a fourth educational course on social connectivity and loneliness. Completion of this initial pilot study will allow for a round of improvements informed by data from the program, on usability, as well as feedback from participants and citizen advisors. This will allow for an iterative process to build the program to its full content, with feedback to optimize the user experience and ensure the accessibility of the content. The information generated from this study will help inform the development of the second program's prototype, expected to benefit from the initial pilot to become more user-friendly, effective and accessible to the target audience. This pilot study will be a longitudinal study of an inception cohort exposed to the HALT-AD online educational program for a four-month study. It will utilize pre- and post- intervention collection of quantitative and qualitative data to evaluate the program's first prototype.


Description:

Healthy Actions and Lifestyles to Avoid Dementia or Hispanos y el ALTo a la Demencia program (HALT- AD) is a novel bilingual educational program that will focus on reducing risk factors with the ultimate goal of preventing dementia. It will be centered around a web-based interactive virtual online platform that will be developed to be dynamic, engaging, and interactive. Through interactive courses, the educational content of HALT-AD will provide guidance on modifiable lifestyle risk factors and the identification of treatable medical conditions including cerebrovascular health, sleep, sensory loss, social isolation, mood, diet, and physical activity. Participants in HALT-AD will be provided with personalized risk profiles, will be encouraged to learn about risk factors and how they can effectively modify them, and will be provided with feedback on their progress. Participants will participate in facilitated support discussion groups, which will focus on the content of the educational material and the invocation of change through participant engagement and compliance. Prior to launching the full HALT-AD program, it is essential that the Sponsor conduct a preliminary pilot study to evaluate the program's first prototype. At the end of the 3-month pilot program, evaluations will include: the usability of- and engagement with- the online platform and users' acceptability of the learning content and facilitated support discussion groups. As well as evaluating preliminary evidence on the effectiveness of the program in changing knowledge, self-efficacy, and dementia-related lifestyle risk factors. The program will also be evaluated on metrics such as being user friendly, engaging, supportive and communicative, with the potential for scalability to state- and national-levels. Aims: 1. To evaluate the usability of, and engagement with, the online platform 2. To determine users' acceptability of: 1. HALT AD program content 2. facilitated support discussion groups 3. To evaluate preliminary evidence on the effectiveness of the program in changing 1. knowledge, 2. self-efficacy, and 3. dementia-related lifestyle risk factors.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date August 24, 2022
Est. primary completion date August 24, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 85 Years
Eligibility Inclusion Criteria: 1. Signed informed consent must be obtained and documented (from the participant). 2. Sufficient proficiency in English or Spanish to undergo clinical assessment and participate in an online educational program. 3. Ages 50-85 4. Montreal Cognitive Assessment-Telephone/Blind Version (T-MoCA) score =18/22 5. Technical ability to participate in an online educational program (i.e. ability to operate a computer/tablet and gain internet access; ability to send and receive emails) 6. Sufficient vision and hearing to participate in online educational program (judgement of site investigator) 7. Ability to sit comfortably for a period of at least 30 minutes Exclusion Criteria: 1. Participants who, in the opinion of the co-PIs, are not able to complete trial procedures or adhere to the schedule of study assessments will be excluded from study participation. 2. Individuals where English or Spanish is not sufficiently proficient for clinical assessment, and participation in a web-based educational program. 3. Participants who do not have sufficient vision and hearing to participate in an online educational program 4. Individuals who do not have the technical ability to participate in an online educational program. Technical ability is defined as ability to operate a computer/tablet and gain internet access; ability to send and receive emails) 5. Total Score on the T-MoCA <18 6. Individuals who have an advanced degree (e.g. Master's, MD, PhD) in an area related to brain health will not be eligible to participate.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
HALT-AD
Prior studies have shown that programs that focus on promoting brain health and managing lifestyle risks (such as poor diet, obesity, physical inactivity, sleep issues, loneliness) may help in preventing or lowering the risk of dementia. To address this, we have developed the HALT-AD program. HALT-AD is an educational program designed to teach about dementia and lifestyle changes that can help preserve brain health and lower dementia risk

Locations

Country Name City State
United States Alzheimer's Disease Cooperative Study (ADCS) La Jolla California

Sponsors (1)

Lead Sponsor Collaborator
Alzheimer's Disease Cooperative Study (ADCS)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Usability of the HALT-AD program Users will complete the HALT-AD User Experience survey which is adapted for HALT-AD based on questions from the User Experience Questionnaire (UEQ) available at https://ueqtryitout.ueq-research.org/. Participants will be asked to decide as spontaneously as possible which conflicting terms (e.g. annoying vs. enjoyable) better describes the HALT-AD program. Additionally, users will be asked one additional question ""How likely is it that you would recommend HALT-AD to a friend or colleague?" on a scale of -100 (extremely unlikely) to +100 (extremely likely). 4 months
Primary Users' engagement with the HALT-AD online platform measuring completion of program assessments User engagement including the percentage of users who started the course, completed the course and passed the course. 4 months
Primary Users' engagement with the HALT-AD online platform measuring the average time spent per user on the course User engagement measuring the average time spent per user on the course. 4 months
Primary Acceptability Survey- Users' acceptability of the HALT-AD program content Qualitative evaluation of participant responses on the HALT-AD Course Acceptability Survey completed at 4 months completed at 4 months
Primary FOCUS Group discussion- Qualitative evaluation of the HALT-AD program content Qualitative evaluation of participant responses during the focus group discussion completed at 4 months. 4 months
Primary Users' satisfaction with the facilitated support discussion groups Description: Qualitative evaluation of participant responses on the HALT-AD Facilitated Discussion Group Acceptability Survey 4 months
Primary Qualitative evaluation of participant responses during the focus group discussion groups Description: Qualitative evaluation of participant responses during the focus group discussion 4 months
Secondary Change from baseline in knowledge on the HALT-AD knowledge assessment survey at 4 months The HALT-AD knowledge assessment survey is developed based on the HALT-AD program content to assess general knowledge of dementia including risk factors, brain health and prevention. Possible scores range from 0 (all answers are incorrect) to 20 (all answers are correct). Change = (4 months score - baseline score) at baseline and 4 months
Secondary Change from baseline in self-efficacy on the New General Self-Efficacy Scale (NGSE) at 4 months. The NGSE is an 8-item validated instrument assessing self-efficacy. Using a 5-point rating scale (1= strongly disagree to 5= strongly agree), participants report how much they believe they can achieve their goals. Total score for each participant is calculated by taking the mean of their ratings on each item. Change = (4 months score - baseline score) at baseline and 4 months
Secondary Change from baseline in lifestyle risk on the HALT-AD lifestyle risk assessment survey at 4 months The HALT-AD lifestyle risk assessment survey is developed by the HALT-AD subject- matter expert team to assess adherence to a potentially dementia risk-reducing lifestyle. Possible scores vary by risk factor. Change = (4 months score - baseline score) at baseline and 4 months
See also
  Status Clinical Trial Phase
Completed NCT05686486 - Gentle Gymnastics and Relationship Between Family Caregivers and Residents With Dementia in Nursing Homes N/A
Terminated NCT05451693 - Outreach-ER: A Dementia Care Intervention Program
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Enrolling by invitation NCT06040294 - Dementia and Disability Simulation for College Nursing Students' Senior Activity Facilitation Skills N/A
Completed NCT05114187 - An Internet-Based Education Program for Care Partners of People Living With Dementia N/A
Recruiting NCT06322121 - Vascular Aspects in Dementia: Part 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Completed NCT04426838 - Cognitive Behavioral Therapy for Insomnia for the Dementia Caregiving Dyad N/A
Recruiting NCT03462485 - Pilot Study of the Effects of Playing Golf on People With Dementia N/A
Active, not recruiting NCT03677284 - Managing Time With Dementia: Effects of Time Assistive Products in People With Dementia N/A
Completed NCT03849937 - Changing Talk Online (CHATO) Study N/A
Recruiting NCT06284213 - Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium
Recruiting NCT05579236 - Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
Completed NCT05080777 - Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems N/A
Completed NCT04571697 - A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy
Completed NCT03583879 - Using Gait Robotics to Improve Symptoms of Parkinson's Disease N/A
Recruiting NCT06033066 - Financial Incentives and Recruitment to the APT Webstudy N/A
Active, not recruiting NCT05204940 - Longitudinal Observational Biomarker Study
Recruiting NCT05684783 - Dementia Champions in Homecare
Completed NCT03147222 - Function Focused Care: Fracture Care at Home N/A